The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Read what ...

The Food and Drug Administration said that 17 serious adverse events, including two that resulted in death, have been reported in worldwide recipients of the vaccine Ixchiq over the age of 60.